Document is current
Any future updates will be listed below
-
Authors
Milani, Michela https://orcid.org/0000-0002-0363-678X
Canepari, Cesare
Liu, Tongyao
Biffi, Mauro
Russo, Fabio
Plati, Tiziana
Curto, Rosalia
Patarroyo-White, Susannah
Drager, Douglas
Visigalli, Ilaria
Brombin, Chiara
Albertini, Paola
Follenzi, Antonia https://orcid.org/0000-0001-9780-300X
Ayuso, Eduard
Mueller, Christian
Annoni, Andrea https://orcid.org/0000-0002-8541-2578
Naldini, Luigi https://orcid.org/0000-0002-7835-527X
Cantore, Alessio https://orcid.org/0000-0002-9741-997X
-
Funding
Funding for this research was provided by:
Fondazione Telethon
Sponsored research agreement by Bioverativ / Sanofi
- License Information
-
More Information
Article History
Received: 30 August 2021
Accepted: 4 April 2022
First Online: 4 May 2022
Competing interests
: L.N., A.C., A.A., M.M., T.L., S.P.W. are inventors on patent applications submitted by Foundation Telethon and San Raffaele Scientific Institute or Bioverativ/Sanofi on LV technology related to the work presented in this manuscript (WO2019/152692; WO2016009326). FT and SRSI, through SR-Tiget, have established a research collaboration on liver-directed lentiviral gene therapy of hemophilia with Bioverativ/Sanofi. The remaining authors declare no competing interests.
